Monopar Therapeutics Inc. (MNPR) has a negative trailing P/E of -27.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 61.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.59%, forward earnings yield 1.62%. PEG 0.14 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -1,101.4 | -25.90 | 461.24 | 0.00 | - |
| 2017 | -83.4 | -0.07 | 143.54 | 0.00 | - |
| 2018 | -427.8 | 5.31 | 199.58 | 0.00 | - |
| 2019 | -208.0 | -7.16 | 69.59 | 0.00 | - |
| 2020 | -53.2 | -1.18 | 21.37 | 0.00 | - |
| 2021 | -22.0 | -0.85 | 10.57 | 0.00 | - |
| 2022 | -14.3 | -1.05 | 14.94 | 0.00 | - |
| 2023 | -2.9 | 0.10 | 4.41 | 0.00 | - |
| 2024 | -16.2 | -0.12 | 4.57 | 0.00 | - |
| 2025 | -35.3 | -0.98 | 0.00 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.11 | $0.00 | $-1.19M | - |
| 2017 | $-1.59 | $0.00 | $-16.56M | - |
| 2018 | $-0.31 | $0.00 | $-3.23M | - |
| 2019 | $-0.39 | $0.00 | $-4.23M | - |
| 2020 | $-0.58 | $0.00 | $-6.31M | - |
| 2021 | $-0.73 | $0.00 | $-9.1M | - |
| 2022 | $-0.83 | $0.00 | $-10.52M | - |
| 2023 | $-0.58 | $0.00 | $-8.4M | - |
| 2024 | $-411.23 | $0.00 | $-15.59B | - |
| 2025 | $-1.85 | $0.00 | $-13.72M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.60 | $-6.13 – $-2.25 | $400K | $122.55K – $541.69K | 10 |
| 2027 | $-3.61 | $-7.16 – $-1.46 | $19.32M | $3.53M – $27.39M | 7 |
| 2028 | $-0.18 | $-0.64 – $0.22 | $93.11M | $28.53M – $126.09M | 8 |
| 2029 | $3.50 | $0.34 – $5.12 | $204.01M | $62.5M – $276.28M | 6 |
| 2030 | $8.14 | $0.80 – $11.88 | $304.78M | $93.37M – $412.73M | 6 |
